Intel $20 billion stock offering prices at $95 after orders

Intel's $20 billion stock offering priced at $95 per share this week, capping a two-day sequence that began with a roughly 4% selloff on dilution fears and ended with institutional orders reportedly totaling $100 billion, about five times the size of the deal. The company upsized the sale from the $15 billion it had announced the day before, and the transaction is expected to close August 12.

Intel is issuing 210,526,315 shares at that price, leaving net proceeds of about $19.7 billion after underwriting discounts and expenses. Underwriters hold a 30-day option to buy up to 31,578,947 additional shares. This is the first common stock offering since Intel's 1971 listing, a useful measure of how far the company's capital needs have climbed.

I read this deal as the clearest signal yet of what the AI compute arms race costs a legacy incumbent. The raise funds the costly build-out of Intel's chip contract manufacturing business, the foundry push meant to win third-party orders. A build-out of that scale does not come cheap, and the equity market is now the piggy bank.

The pricing itself is the market's verdict. At $95, Intel sold shares at a 2.6% discount to the prior close, a modest concession for a deal this size. Monday's dip showed the fear: dilution would wipe out existing holders. The order book showed the reality: institutions wanted in at almost any price.

The counter-argument deserves a fair hearing. Diluting shareholders to fund a foundry that may not produce profits for years is a real cost, and Intel's own description of the proceeds is vague: general corporate purposes, possibly capital expenditures and working capital. That leaves genuine uncertainty about where the cash lands. I do not think it changes the strategic read: a raise this size only makes sense as foundry fuel.

The deal's structure points the same way. J.P. Morgan, Goldman Sachs, Morgan Stanley and Citigroup acted as joint book-running managers, with Barclays, BofA Securities, Deutsche Bank Securities, Mizuho, RBC Capital Markets, Wells Fargo Securities and others on the syndicate. A bench that deep, on a shelf registration filed with the SEC, reads as a prepared move rather than a scramble.

What the Intel $20 billion stock offering says about chip capex

For investors, the Intel $20 billion stock offering carries an uncomfortable lesson. Even a company with Intel's history now pays for growth by issuing stock at a discount instead of slowing its build-out. If the foundry bet lands, the dilution becomes a rounding error; if it stumbles, shareholders absorb both the capex and the higher share count. That asymmetry is the real story of the AI arms race.

The greenshoe matters too. If the underwriters exercise their option in full, Intel collects about $3 billion more on top of the $19.7 billion. Either way, the cash lands this month and the foundry program has its funding.

Why this matters

Intel chose dilution over delay, and that is the decision to watch. The money funds a build-out whose payoff runs years out, and the share count is permanently larger. For anyone holding the stock, the question is no longer whether Intel can raise capital. It is whether foundry revenue ever arrives to justify the price paid for it.

Sources

Intel Announces Upsize and Pricing of $20 Billion Common Stock Offering

Photo by Brecht Corbeel on Unsplash

✔Human Verified

Researched and cross-referenced against primary sources by the Bytevyte editorial team. This article was generated with the assistance of artificial intelligence and reviewed by the Bytevyte editorial team.

What the Intel $20 billion stock offering says about chip capex

Why this matters

Sources

Related Articles